Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TEVA 
Teva Pharma Industries Ltd ADR (TEVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: TEVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.44
1 Year Target Price $24.44
| 6 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.42% | Avg. Invested days 65 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.50B USD | Price to earnings Ratio - | 1Y Target Price 24.44 |
Price to earnings Ratio - | 1Y Target Price 24.44 | ||
Volume (30-day avg) 11 | Beta 0.71 | 52 Weeks Range 12.47 - 22.80 | Updated Date 10/28/2025 |
52 Weeks Range 12.47 - 22.80 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When Before Market | Estimate 0.67 | Actual - |
Profitability
Profit Margin -0.94% | Operating Margin (TTM) 21.41% |
Management Effectiveness
Return on Assets (TTM) 5.37% | Return on Equity (TTM) -2.42% |
Valuation
Trailing PE - | Forward PE 7.06 | Enterprise Value 37628450176 | Price to Sales(TTM) 1.35 |
Enterprise Value 37628450176 | Price to Sales(TTM) 1.35 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 19.81 | Shares Outstanding 1147150917 | Shares Floating 1142218168 |
Shares Outstanding 1147150917 | Shares Floating 1142218168 | ||
Percent Insiders - | Percent Institutions 64.69 |
Upturn AI SWOT
Teva Pharma Industries Ltd ADR
Company Overview
History and Background
Teva Pharmaceutical Industries Ltd. was founded in 1901 in Jerusalem. Initially a distributor of imported medicines, it grew organically and through acquisitions, becoming a global leader in generic pharmaceuticals and specialty medicines. Key milestones include the acquisitions of Ratiopharm in 2010 and Allergan's generics business in 2016, though the latter proved financially challenging.
Core Business Areas
- Generics: Teva is the world's largest generic drug manufacturer, producing and selling a wide range of generic medicines across various therapeutic areas.
- Specialty Medicines: This segment focuses on branded specialty medicines, primarily in central nervous system (CNS) and respiratory therapeutic areas. Key products include Austedo for Huntington's disease and tardive dyskinesia, and ProAir Digihaler for asthma and COPD.
- Biosimilars: Teva develops and markets biosimilar versions of complex biologic drugs.
Leadership and Structure
Teva is led by CEO Richard Francis. The organizational structure includes distinct business units for generics, specialty medicines, and R&D, with global operations and commercial teams.
Top Products and Market Share
Key Offerings
- Copaxone: A multiple sclerosis treatment; used to be a major revenue driver but faces generic competition. Competition includes Biogen's Avonex and other MS treatments. While it faces steep competition, the Copaxone franchise generated $1.1 billion in revenue for Teva in 2023.
- Austedo: A treatment for Huntington's disease and tardive dyskinesia. Faces competition from Ingrezza (valbenazine) by Neurocrine Biosciences. Austedo generated $1.2 billion revenue for Teva in 2023.
- ProAir Digihaler: Digital inhaler for Asthma and COPD. Primary competitor is albuterol inhalers from Mylan and other generics companies.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition from both branded and generic drug manufacturers. Growth is driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug development.
Positioning
Teva is a leading global generic pharmaceutical company, but it also has a significant presence in specialty medicines and biosimilars. Its competitive advantages include its scale, global reach, and R&D capabilities, but it faces challenges related to debt, pricing pressure, and competition.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to reach over $1.7 trillion by 2027. Teva is positioned to capture a share of this TAM through its diverse product portfolio, focusing on both generics and innovative treatments. Generics account for roughly 40% of pharmaceutical sales by volume.
Upturn SWOT Analysis
Strengths
- Global scale and reach
- Diversified product portfolio
- Strong R&D capabilities in generics and specialty medicines
- Established manufacturing and distribution network
- Leading position in the generics market
Weaknesses
- High debt burden
- Exposure to pricing pressure in the generics market
- Dependence on key products facing generic competition
- Past challenges with integration of acquisitions
- Complex organizational structure
Opportunities
- Growing demand for generic medicines in emerging markets
- Development and launch of new specialty medicines
- Expansion of biosimilars portfolio
- Strategic partnerships and collaborations
- Cost optimization and efficiency improvements
Threats
- Intense competition from other generic and branded drug manufacturers
- Increased regulatory scrutiny and pricing controls
- Patent expirations and loss of exclusivity
- Product liability and litigation risks
- Economic downturns and healthcare reforms
Competitors and Market Share
Key Competitors
- VTRS
- RDY
- Mylan (part of VTRS)
Competitive Landscape
Teva's large global size provides strong competition as well as it's large product portfolio. However, VTRS has shown to be stronger and more stable recently.
Major Acquisitions
Actavis Generics (Allergan)
- Year: 2016
- Acquisition Price (USD millions): 40500
- Strategic Rationale: To expand Teva's generics business and become the largest generics manufacturer globally. This acquisition resulted in significant debt for Teva.
Growth Trajectory and Initiatives
Historical Growth: Teva experienced significant growth through acquisitions, but this has been followed by a period of restructuring and debt reduction. Historical revenue growth has been inconsistent.
Future Projections: Analysts project modest revenue growth for Teva, driven by new product launches and cost optimization. Profitability is expected to improve as the company reduces its debt and streamlines operations.
Recent Initiatives: Teva has implemented a restructuring plan focused on reducing costs, improving operational efficiency, and divesting non-core assets. The company is also investing in R&D to develop new specialty medicines and biosimilars.
Summary
Teva Pharmaceutical is a global leader in generic and specialty medicines. Although burdened by significant debt from past acquisitions, the company is undergoing restructuring and cost optimization. The company has positive cash flow. The company's strength is in its extensive product portfolio and global reach, while threats exist in pricing pressures and competition. The focus should be on R&D and reduce debt to further growth and stability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Teva Pharmaceutical Industries Ltd. SEC Filings
- Industry reports (e.g., IQVIA, EvaluatePharma)
- Analyst reports from major investment banks
- Company press releases and investor presentations
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market data and analyst estimates are subject to change and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Teva Pharma Industries Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Richard D. Francis | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 37000 | Website https://www.tevapharm.com |
Full time employees 37000 | Website https://www.tevapharm.com | ||
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.